Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
100 mg | Inquiry | 7-10 days | |
500 mg | Inquiry | 7-10 days |
Description | Danegaptide (GAP-134), has been identified as a potent and selective second generation gap junction modifier with oral bioavailability.a small modified dipeptide. |
In vitro | Danegaptide (GAP-134) is a pharmalogical agent with a favorable clinical safety profile and potential antiarrhythmic efficacy, as already confirmed in phase I clinical trials.Gap junction uncoupling can alter conduction pathways and promote cardiac re-entry mechanisms that potentiate many supraventricular arrhythmias, such as atrial fibrillation (AF) and atrial flutter (AFL).?Gap junction modifier Danegaptide (GAP-134), showed consistent efficacy on measures of conduction and AF/AFL inducibility in the canine sterile pericarditis model. |
Alias | ZP 1609, GAP-134 |
Molecular Weight | 291.3 |
Formula | C14H17N3O4 |
Cas No. | 943134-39-2 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.